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Abstract
Background: The prevalence of type II diabetes among individuals suffering from schizophrenia or schizoaffective
disorders is more than double that of the general population. By 2005, North American professional medical
associations of Psychiatry, Diabetes, and Endocrinology responded by recommending continuous metabolic
monitoring for this population to control complications from obesity and diabetes. However, these
recommendations do not identify the types of effective treatment for people with schizophrenia who have type II
diabetes. To fill this gap, this systematic evidence review identifies effective lifestyle interventions that enhance
quality care in individuals who are suffering from type II diabetes and schizophrenia or other schizoaffective
disorders.
Methods: A systematic search from Medline, CINAHL, PsycINFO, and ISI Web of Science was conducted. Of the
1810 unique papers that were retrieved, four met the inclusion/exclusion criteria and were analyzed.
Results: The results indicate that diabetes education is effective when it incorporates diet and exercise
components, while using a design that addresses challenges such as cognition, motivation, and weight gain that
may result from antipsychotics.
Conclusions: This paper begins to point to effective interventions that will improve type II diabetes management
for people with schizophrenia or other schizoaffective disorders.
Background
In 2005, the World Health Organization (WHO) predicted
that the prevalence of type II diabetes will double by 2030,
to affect 366 million people globally [1]. Consequently
WHO developed an action plan to increase access to type
II diabetes healthcare by 2013 [2]. The increasing rate of
this chronic illness is a concern because when glucose
(sugar) cannot be absorbed by vital organs, glucose
remains in the bloodstream. This leads to persistently high
blood glucose levels, which is used as an indicator in dia-
betes management. Consistently high blood glucose is
linked to complications such as cardiovascular disease,
blindness, neuropathy, kidney failure, and poor wound
healing resulting in infection that may lead to amputation
[3].
Not everyone is at equal risk for the development of this
chronic illness. Individuals suffering from schizophrenia
and schizoaffective disorders are at a greater risk of type II
diabetes, with prevalence rates reaching more than two
times those of the general population [4-6]. While it has
been reported that people with schizophrenia may be
genetically predisposed to type II diabetes, several other
risk factors could contribute to the development of type II
diabetes among people with schizophrenia [7]. Some anti-
psychotic medications such as olanzapine and clozapine,
can cause side effects that promote the onset of type II
diabetes [8-10]. These side effects include weight gain, dys-
lipidemia, hypertension, cardiovascular disease and
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any medium, provided the original work is properly cited.decreased glucose tolerance [4,6,11]. Furthermore, El-Mal-
lakh [6] observed that poorer health is exacerbated due to
high rates of unemployment and reliance on social sup-
port, often leaving patients without financial resources to
follow dietary guidelines.
Between 2004 and 2005, the debilitating health chal-
lenges associated with schizophrenia were recognized by
the American Psychiatric Association (APA), American
Diabetes Association (ADA), Canadian Diabetes Associa-
tion (CDA), American Association of Clinical Endocri-
nologists (AACE), and the North American Association
for the Study of Obesity (NAASO) [4,12]. These profes-
sional associations recommended continuous metabolic
monitoring as a strategy to both prevent and diagnose
type II diabetes [4]. Additionally, the need for interdisci-
plinary care incorporating psychiatrists, psychiatric
nurses, family physicians, and diabetes specialists was
recognized in response to the complexity of these com-
bined illnesses [12]. However, effective treatment was not
included for people with schizophrenia who have type II
diabetes.
Given the risk of diabetes-related complications, the
ADA and the CDA recommend that all individuals with
type II diabetes be provided with Diabetes Self-Manage-
ment Education (DSME) to successfully control their
blood sugar [13,14]. Although DSME that incorporates
lifestyle interventions are employed for the general popu-
lation with type II diabetes, such programs are rarely
offered to people who experience schizophrenia and who
have type II diabetes. This is reflective of the fact that
this population receives poorer diabetes care compared
to those without severe mental illness [15,16]. Goldberg
et al. [15] found that the frequency of screening and
monitoring exams, such as tests for glycated hemoglobin
(HbA1c), eye examinations, and identifying serum fat
levels, were not meeting the ADA’sa n dC D A ’sr e c o m -
mendations. Individuals with schizophrenia were also less
likely to receive diabetes education. Dickerson et al. [17]
found that 48% of participants with severe mental illness
had not received diabetes education within the last 6
months. As a result, this population experiences higher
rates of hospitalization for hyper or hypoglycaemic epi-
sodes, and for infections [18].
Taken together, suboptimal diabetes care quality and the
absence of effective treatment recommendations for peo-
ple who have type II diabetes and schizophrenia or schi-
zoaffective disorders is contributing to a life expectancy
that is 20% lower than the general population [18,19]. In
response to the need for evidence on this topic, this sys-
tematic evidence review (SER) will identify effective life-
style interventions that enhance quality care in individuals
who have type II diabetes and schizophrenia or schizoaf-
fective disorders. Thus, the results from this review can be
used to improve type II diabetes management, thereby
reducing the burden on the healthcare system from the
complications associated with chronically high blood
glucose.
Methods
Literature search
Electronic searches using Medline, PsycINFO, CINAHL,
and ISI Web of Science databases were conducted on
June 15, 2011. The search strategies, which are pre-
sented in Table 1, were developed in consultation with
SB, a librarian scientist. The literature search yielded the
identification of 1810 possibly eligible studies. From
these, 920 abstracts were retrieved from Medline, 411
from PsycINFO, 88 from CINAHL and 391 from ISI
Web of Science.
Eligibility assessment
Each title and abstract was independently screened by AC
and ES in accordance with the following inclusion criteria
that was developed a priori: i) study participants must
have a medical diagnosis of both type II diabetes and schi-
zophrenia or schizoaffective disorder, ii) the intervention
must target a lifestyle factor associated with diabetes self-
care, such as problem-solving skills, education classes, diet
or exercise, iii) the outcome measures that determine the
success of the intervention must either consider HbA1c,
fasting blood glucose (FBG), body mass index (BMI) or
weight lost (measured in pounds or kilograms). Interven-
tions that did not exclusively recruit individuals with schi-
zophrenia or schizoaffective disorder were considered.
S t u d i e sw e r ee x c l u d e di ft h e yw e r ei nal a n g u a g eo t h e r
than English, French, Italian or Greek; focused on meta-
bolic syndrome, genetics or screening; or considered risk
factors for developing type II diabetes without testing an
intervention. Abstracts were also read if a title did not pro-
vide sufficient information for exclusion. After considering
abstracts for eligibility, full text articles were rated for elig-
ibility. In accordance with an inter-rater reliability of 0.40,
disagreements between AC and ES were discussed with a
third rater, CSD, and a collective consensus was reached.
The eligible articles were subsequently rated for quality,
and relevant references were considered.
Quality assessment
A 13-item quality assessment checklist was adapted from
Lagerveld et al. [20,21]. Items assessed study design,
intervention measurements, outcome measurements, and
the presentation of data and analysis. Additional file 1
contains a complete list of items. Each study that met the
inclusion/exclusion criteria was independently screened
by AC and ES for quality assessment criteria adapted and
developed a priori. The inter-rater reliability was 0.62. All
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ing was reached through consensus between the two
independent raters.
Articles that met all quality items were considered excel-
lent. Papers were rated fair and excluded if they had any of
the following exclusion criteria: i) does not state the main
features of the population which was defined as stating the
recruitment location, geographic location, age, gender and
eligibility criteria; ii) no account for lifestyle factors during
data collection and analysis; iii) follow-up measurements
do not include HbA1c, BMI, weight loss, and/or FBG.
Therefore, a study was considered good if it did not meet
the criteria to be considered fair, but lost other quality
points, such as not discussing initial participation rates,
and not using appropriate statistical methods or calculat-
ing statistical significance.
Results
Determining relevant literature
The systematic search of four databases (Medline, Psy-
cINFO, CINAHL, and Web of Science) yielded a total of
1810 unique studies. Raters AC and ES independently
screened titles and eliminated those that met the exclusion
criteria. A total of 304 abstracts were reviewed in accor-
dance with the inclusion/exclusion criteria. Of these, 49
full-text articles were retrieved. Four articles met the final
inclusion criteria. This process of inclusions and exclu-
sions is depicted in Figure 1.
The following is a list of reasons for excluding the 45
full text articles: i) A total of 2.2% (n = 1) was a textbook
chapter that elaborated on a study already included; ii)
Another 2.2% (n = 1) proposed an intervention that
would hypothetically be effective without testing its effec-
tiveness; iii) 4.4% of articles (n = 2) were interventions
where outcome measurements did not include blood glu-
cose or weight assessment; iv) A total of 15.6% (n = 7)
did not include both type II diabetes and schizophrenia
in the study population; v) Another 22.2% of the articles
(n = 10) focused on increasing glycaemic control through
changing medication, without addressing lifestyle factors;
vi) The remaining 53.3% of papers (n = 24) did not assess
the effectiveness of an intervention.
Methodological quality
The four articles that met all inclusion criteria were
assessed using the methodological quality assessment
checklist that categorized articles as being excellent,
good or fair. Of these, three were assessed to be excel-
lent, and the remaining study was rated good. Thus, no
articles were excluded at this step, because all met qual-
ity criteria good or better.
Characteristics of included studies
The significant characteristics of each paper are pre-
sented in Table 2. Major findings of each intervention
analyzed are presented in Table 3. The included articles
also shared common elements: each study recruited par-
ticipants from different US states; they all considered the
older-adult population, as indicated by the mean partici-
pant age ranging between 44-53 years; interventions each
Table 1 Search Terms used for Medline search strategy
Database Search Terms
Medline (exp Diabetes Mellitus type 2 OR Diabe*.mp.) AND (exp “Quality of Health Care” OR exp. Access to information OR access.mp. OR
exp.Evaluation studies as topic OR treatment.mp. OR exp.Early intervention (Education) OR intervention.mp. OR interdiscipl*
treatment approach.mp. OR treatment effectiveness evaluation.mp. OR effective intervention.mp. OR evaluat*.mp. OR exp.delivery
of health care OR exp.Treatment Outcome OR treatment outcom*.mp. OR clinical practice.mp. OR effective treatment.mp. OR
blood glucose self-monitoring/OR exp drug monitoring OR exp.Life Style OR lifestyle intervention.mp. OR exp.Problem Solving OR
problem solv*.mp.) AND (exp.schizophrenia OR exp.psychotic disorder OR early psych*.mp. OR first episod* psych*.mp. OR first
onset psych*.mp, “schizophrenia and disorders with psychotic features” OR early psychosis.mp. OR first episod* psychosis.mp. OR
first onset psychosis.mp. OR first onset psych*.mp)
PsycINFO (Diabete* OR Diabetes OR exp. Diabetes) AND (exp Treatment OR intervention OR interdisciplinary treatment approach OR exp
Early Intervention OR treatment effectiveness evaluation OR “quality of care” OR effective intervention.mp. OR exp Evaluation OR
evaluat*.mp. exp Health Care Delivery OR exp Treatment Outcomes OR treatment outcom*.mp. OR exp Clinical Practice/OR clinical
practice.mp.OR effective treatment.mp. OR exp Lifestyle Changes/OR lifestyle intervention.mp. OR exp Problem Solving/OR
problem solv*.mp. OR treatment) AND (schizo* OR early psych* OR first episod* psych* OR first onset psych* OR exp.schizophrenia
OR acute psychosis OR psychosis OR first episode* psychosis.mp.)
ISI Web of
Science
(Diabete* OR Diabetes AND (effective intervention OR quality care OR access OR evaluation OR health care quality OR quality
health care OR treatment outcome OR effective treatment OR clinical practice OR lifestyle intervention OR problem solv* OR
intervention OR interdiscplinary treatment approach OR early intervention OR treatment effectiveness evaluation) AND (schizo* OR
early psychosis OR early psych* OR first episod* psych* OR first episode* psychosis OR first onset psych* OR first onset psychosis)
CINAHL (Diabet* OR MH Diabetes Mellitus) AND (MM.Clinical Effectiveness OR intervention* OR MH.Quality of Health Care OR MM.Quality
of Care Research OR quality care OR MH.Access to Information OR access OR health care quality OR MH.Treatment Outcomes OR
MM.Outcomes of Education OR MH.Outcomes Health Care OR treatment outcome* OR effective treatment OR MM.Practice
Patterns OR clinical practice OR MH.Life Style OR lifestyle intervention OR MH. Problem Solving OR problem solv* OR early
intervention OR MM.Program Evaluation OR MM.Glycemic Control or glycemic control OR MM.Self-Efficacy or self*efficacy OR MH.
Self Care OR self*care) AND (MH.Schizophrenia OR MM.Schizophrenia, Childhood OR MM.schizoaffective Disorder OR MH Psychotic
Disorders OR schizo* OR early psych* OR first episod* psych* OR first onset psych*)
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they also incorporated components that addressed the
challenges associated with this particular population,
such as decreased cognitive ability and reduced motiva-
tion [22,23]. For example, inpatient modules in Linden-
mayer’s et al. [24] study were taught for four months
before initiating a new level. Some of McKibbin et al.’s
[23] strategies involved gradually introducing new topics,
utilizing memory aids, and providing minimal text so as
to simplify messages. One important difference to note is
the variation in study locations: two programs recruited
from a psychiatric hospital inpatient setting [24,25]. The
remaining two articles addressed health needs of indivi-
duals in out-patient mental health settings, such as
board-and-care accommodations and community club-
houses [23,26].
Results of in-patient interventions
Both in-patient programs provided information regarding
the importance of exercise, a n dp r o v i d e ds t r a t e g i e sf o r
making this lifestyle change [24,25]. After enhancing
patient motivation through classes, achieving physical
activity recommendations in both studies were promoted
by providing exercise facilities. Lindenmayer et al.’s [24]
Figure 1 Flowchart of literature search results and inclusions/exclusions.
Table 2 Summary of Article Characteristics
Author Year Location Study Design Length of
Intervention
Sample
Size
Mean Participant
Characteristics
Location Type of
Intervention
Lindenmayer
et al.
2009 US retrospective, no
control group
12 months 275 (72
diabetes)
mean age: 44.25, 78.5% had a
psychotic disorder
Inpatient Psychoeducation
Teachout et
al.
2011 US pre-test post-test, no
control group
6 months 13 mean age: 45, 85% had a
psychotic disorder,
Inpatient Diabetes
Education
McKibbin et
al.
2006 US RCT 6 months 64 mean age: 53, all had a
psychotic disorder
Outpatient Psychoeducation
McKibbin et
al.
2010 US RCT 12 month
follow-up
52 mean age: 52.4, all had a
psychotic disorder
Outpatient Psychoeducation
RCT = Randomized Control Trial
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Author Year Diabetes Knowledge Outcome Average Weight Loss (lbs) BMI (Kg/m2) Reduction Blood Glucose (mg/DL) Reduction HbA1c (%) Reduction
Lindenmayer et al. 2009 All subjects:
Nutrition/healthy lifestyle
BL = 17.1/30, change @
6M = 20.82/30 (P < 0.001);
Fitness and exercise module
BL = 16.97/30, change @
6M = 20.27/30 (P < 0.001)
Diabetes: 5.98 (P = nr),
Non-diabetes: 4.46 (P = nr)
Diabetes:
BL = 33.94, change @
6M = 30.55 (P = nr);
non-diabetes
BL = 29.55, change @
6M = 27.36 (P = nr)
Diabetes:
BL = 115.84, change @
12M = 98.05 (P < 0.001);
non-diabetes:
BL = 92.81 change @
12M = 87.69 (P = nr)
Teachout et al. 2011 20.35 (P = nr) 40% in the recommended range of 90-110
McKibbin et al. 2006 DART:
BL = 0.5, change @
6M = 0.7 (P < 0.001);
UC:
no change (P < 0.001)
DART:
5.1 (P < 0.001);
UC:
-6.8 (P < 0.001)
DART:
BL = 33.6, change @
6M = 32.9 (P < 0.001);
UC:
BL = 32.9, change @
6M = 33.9 (P < 0.001)
DART:
BL = 163.9, change @
6M = 125.7 (P = ns)
UC:
BL = 147.2, change @
6M = 143.4 (P = ns)
DART:
BL = 7.4, change @
6M = 6.9; (P = ns)
UC:
BL = 6.7, change @
6M = 6.8 (P = ns)
McKibbin et al. 2010 DART:
BL = 0.5, change @
6M = 0.6 (P < 0.01);
UC:
no change (P < 0.01)
DART:
BL = 33.9, change @
6M = 32.9 (P < 0.01);
UC:
BL = 32.6, change @
6M = 34.0 (P < 0.01)
DART:
BL = 7.3 change @
12M = 6.9 (P = ns);
UC:
BL = 6.8, change @
12M = 7.9 (P = ns)
BL = Baseline measurement; 6M = 6 month follow-up; 12M = 12 month follow-up; DART = Diabetes Awareness and Rehabilitation Training experimental group; UC = Usual Care control group; nr = not reported; ns
= not statistically significant
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9knowledge assessment of the four month fitness and
exercise module demonstrated an improvement in scores,
as they increased from 56.6% to 67.6% (P < 0.001). Parti-
cipants in Teachout et al.’s [25] intervention were given
additional resources: pedometers, encouragement to
walk, and yoga classes. Fitness knowledge was not
assessed following the intervention.
In both studies, nutrition lessons were aimed at improv-
ing dietary habits. In Lindenmayer et al.’s [24] program,
workshops provided dietary tips and a weekly 25 dollars
was given to enable the purchase of healthy foods. This
strategy was successful as the knowledge assessment scale
for the four month section on nutrition and healthy life-
style increased from 57% to 69.4% (P < 0.001). Teachout
et al.’s [25] method involved modules on healthy meal
planning, shopping and food preparation over a period of
six months. However, participant knowledge gained from
this approach was not measured.
Overall, the psychiatric in-patient interventions had a
positive impact on weight, BMI and blood glucose mea-
surements, thus indicating the effectiveness of combining
diet and exercise. After 12 months, participants with type
II diabetes and severe mental illness in Lindenmayer et
al.’s [24] trial lost a mean total of 5.98 lb. BMI was also
reduced from 33.94 kg/m2 to 30.55 kg/m2 (statistical sig-
nificance was not calculated for BMI or weight loss).
Furthermore, blood glucose also decreased significantly,
from an average of 115.85 mg/DL to 98.05 mg/DL (P <
0.001). This reduction was significantly related to the
nutrition module that was completed during the beginning
of the intervention. Similarly, all of Teachout et al.’s [25]
participants reduced their weight, with an average loss of
20.35 lb, and 40% of fasting glucose levels met the recom-
mended value as outlined by the ADA (statistical signifi-
cance was not calculated).
Results of out-patient interventions
In McKibbin et al.’s [23] six month Diabetes Awareness
and Rehabilitation Training (DART), participants received
90-min weekly sessions providing diet, exercise and other
diabetes self-care strategies such as monitoring blood glu-
cose levels. Physical activity modules involved learning
about the different types of exercise, how being active can
impact blood glucose, and how to keep track of daily exer-
cise. Participants were also given pedometers, encouraged
to walk, and tracked weekly weight changes to increase
motivation.
Participants additionally received simplified nutrition
education that provided knowledge of the different food
groups, adequate portion sizes, healthy meal planning
and label reading, as well as substituting sugar con-
sumption with fat and fibre.
Comparing the outcome measurements of the DART
program with a Usual Care (UC) group that received
pamphlets from the ADA and continued seeing their
family physician indicated the effectiveness of the DART
intervention. While the control group gained a total of 6.8
lbs during the study period, intervention participants lost
an average of 5.1 lbs (P < 0.001). Correspondingly, DART
participants’ BMI was reduced on average from 33.6 kg/
m2 to 32.9 kg/m2, whereas the UC increased from 32.9
kg/m2 to 33.9 kg/m2 (P < 0.001). Study participants also
enhanced their diabetes knowledge from 0.5 to 0.7, while
there was no change in the scores for the control group (P
< 0.001). Although there was a reduction in fasting blood
glucose and HbA1c in both the experimental and control
group, findings were not statistically significant.
The effectiveness of this intervention was measured
six months after the end of the study [26]. The DART
group maintained their average BMI of 32.9 kg/m2,
while the control group continued to gain weight, total-
ing an average of 34 kg/m2. Although diabetes knowl-
edge dropped at 12 months from 0.7 to 0.6, it was still
higher than the baseline value of 0.5. Therefore, the fol-
low-up study revealed that sustainable skills were gained
from the DART intervention.
Discussion
The current literature assessing the management of type
II diabetes for individuals with schizophrenia and schi-
zoaffective disorders has indicated that there are a num-
ber of tactics used to manage blood glucose levels. One
that has drawn attention involves changing the antipsy-
chotics prescribed. Antipsychotics have been the focus
because of the weight gain and glucose intolerance that
is associated with use of these medications [4,5,11]. A
meta-analysis conducted by B a r n e t te ta l .[ 1 0 ]r e p o r t e d
that patients treated with clozapine and olanzapine have
higher rates of weight gain and therefore increased diag-
nosis of type II diabetes compared to other antipsycho-
tics. Consistent with these findings are case studies that
changed antipsychotic medications as an intervention to
manage blood glucose in type II diabetes. Lerner et al.
[27] lowered the dose of olanzapine for two patients and
noted a reduction in blood glucose levels. Furthermore,
a total of four case studies observed a remission of type
II diabetes upon the replacement of olanzapine with ris-
peridone, as HbA1c levels normalized [28-31]. Given the
impact of antipsychotic medications in the development
of this disease, recommendations are often made to
change prescriptions if persistent weight gain and onset
of type II diabetes occurs [10,12,32]. However, this treat-
ment approach poses challenges because individuals
with schizophrenia may experience a relapse of psycho-
tic or depressive symptoms during the transition period
between medications [33,34]. Moreover, not every indi-
vidual has a therapeutic response to all antipsychotics
[35].
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medication, our SER aimed at determining effective deliv-
ery of diet and lifestyle interventions to enable manage-
ment of type II diabetes in individuals with schizophrenia
or schizoaffective disorders. The success of diet and life-
style interventions to prevent or manage type II diabetes
in individuals with and without schizophrenia or schi-
zoaffective disorders has been documented in the litera-
ture. Menza et al. [36] conducted a 12-month lifestyle
intervention that combined diet and physical activity in
patients with schizophrenia and schizoaffective disorders.
Findings included reduced weight and BMI, increased
nutritional knowledge, and improved HbA1c levels, thus
minimizing risk of type II diabetes development. Torger-
son et al. [37] was successful in preventing the onset of
type II diabetes in obese individuals by combining weight
loss with the inhibition of an enzyme that breaks down
fats. Additionally, Lim et al.’s [38] paper suggests that
weight loss enabled by restricting calories to 600 kcal/day
is an effective method to decrease BMI within the general
type II diabetes population (P < 0.05). Calorie restriction
also corresponded to greater blood glucose control, as
glycated hemoglobin decreased to normal levels in 8
weeks (P < 0.05).
While the relationship between lifestyle interventions
with weight loss and improved glycated hemoglobin is
well documented, the most effective way of delivering
DSME is not always clear for individuals with schizophre-
nia or schizoaffective disorders. Therefore, our paper
makes an important contribution to the literature by high-
lighting effective DSME strategies to support the integra-
tion of healthy habits into lifestyle. Each DSME lifestyle
intervention reviewed in our paper observed reduced
weight and BMI in the presence of intervention strategies
that addressed the challenges associated with schizophre-
nia, such as decreased cognitive ability, reduced motiva-
tion and limited access to resources [6,22,23].
Additionally, Lindenmayer et al. [24] and Teachout et al.
[25] observed that diet can reduce fasting blood glucose.
One drawback consistent in all interventions was the
absence of finding statistical significance when HbA1c
levels were reduced. One likely explanation is the fact that
interventions were not long enough to observe changes in
HbA1c levels [23,39]. This is because retrieving an accu-
rate measure may require blood glucose to be controlled
for more than three months. If lifestyle changes were not
fully adopted, it would be more difficult to see a reduction
in HbA1c, even if some changes occurred. In contrast,
blood glucose measures depict blood glucose at one point
in time and this value can fluctuate hourly. Thus, HbA1c
is considered a more reliable measure of overall blood glu-
cose control. Additionally, HbA1c has been correlated
with diabetes complications, while blood glucose has not
[39].
Because all quality ratings of the analyzed studies
resulted in excellent and good assessments, there is a
strong level of evidence to support our conclusion made
in this SER [40]. However, while the findings of this
paper indicate that lifestyle interventions positively
impact type II diabetes management, there were limita-
tions associated with the heterogeneity of the study set-
tings included in the analysis. In the psychiatric inpatient
setting, participation in the interventions was structured
in the individual’s daily routine. Conversely, in McKibbin
et al.’s [23] study, recruitment from community club-
houses and board-and-care facilities indicates that parti-
cipant involvement required a greater level of self-
motivation. Therefore, care needs to be taken if inpatient
interventions are adapted in outpatient settings, because
individuals within the community may have limited
access to fitness resources, such as gym equipment and
safe areas to exercise.
As a result of limiting searches to four databases con-
taining primarily peer-reviewed material, a potential publi-
cation bias is an additional limitation of this SER.
However, the databases searched covered an extensive
scope of clinical disciplines that were relevant for the nat-
ure of the research question: PsycINFO captures psycholo-
gical literature, CINAHL retrieves the nursing and allied
health, Medline contains medical literature, while ISI Web
of Science is multidisciplinary. Additionally, while grey lit-
erature was not searched for directly, PsycINFO includes
doctoral theses available in Dissertations Abstracts Inter-
national. Additionally, due to a lack of fluency in languages
other than English, French, Italian and Greek, papers in
other languages were not considered.
While the analyzed studies indicate the short-term effec-
tiveness of lifestyle interventions in individuals with type II
diabetes and schizophrenia, the long-term sustainability of
treatment outcomes has not been explored. Additionally,
it has been observed that such lifestyle interventions are
effective for older adults with type II diabetes and schizo-
phrenia. However, the success of such approaches within
the first episode population is unknown. Although adults
over 40 years of age are an important population to con-
sider due to the increased risk factors of diabetes from
long-term use of antipsychotics and being over the age of
45, the onset of type II diabetes in individuals aged 20 to
49 years is increasing [12,41,42]. Therefore, an additional
recommendation for future research involves determining
the effectiveness of such programs for youth and young
adults experiencing early-onset psychosis who also have
type II diabetes.
Overall, the current state of the literature suggests
promise within this line of inquiry. However, our review
also indicates that there are gaps in the current litera-
ture. Of additional significance is the need for interdisci-
plinary teams when addressing the complex health
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diabetes [12].
Conclusion
Findings of this SER suggest that lifestyle interventions
can be effective in managing type II diabetes in patients
that concurrently have schizophrenia or schizoaffective
disorders. However, they should be sensitive to the
unique challenges associated with type II diabetes and
schizophrenia. These challenges include decreased cogni-
tion and motivation, limited resources, as well as negative
side effects (i.e. loss of energy and weight gain) that may
result from antipsychotics. Successful strategies involved
positive encouragement to make changes, gradual intro-
duction of new concepts and skills relating to diet and
exercise, conveying simple messages for complex topics
such as food skills relating to cooking and planning
meals, and incorporating memory aids [23,24].
The findings of this review indicate a strong level of
evidence; there are effective interventions for people with
schizophrenia and type II diabetes. However, there is a
need for continued research to fill gaps. These include
exploration of the long-term sustainability of DSME life-
style interventions, and addressing the young adult popu-
lation suffering from schizophrenia or schizoaffective
disorders with type II diabetes. Furthermore, the need for
interdisciplinary interventions should be kept in mind, as
the collective expertise of psychiatrists, psychiatric
nurses, family physicians and diabetes educators such as
dietitians are all needed. Taking these factors into
account will enable policies and interventions to be
developed that improve the healthcare and quality of life
of individuals with type II diabetes and schizophrenia or
schizoaffective disorders.
Additional material
Additional file 1: Quality assessment checklist; The additional file
contains the quality checklist criterion that was used to determine
the quality of the papers being analyzed for the systematic review.
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